Max Masucci
Stock Analyst at TD Cowen
(0.14)
# 4,546
Out of 5,245 analysts
18
Total ratings
15%
Success rate
-34.62%
Average return
Main Sectors:
Stocks Rated by Max Masucci
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BRKR Bruker | Maintains: Hold | $74 → $72 | $45.69 | +57.58% | 1 | Aug 7, 2024 | |
| BLFS BioLife Solutions | Maintains: Outperform | $29 → $25 | $23.95 | +4.38% | 1 | Aug 9, 2023 | |
| GH Guardant Health | Maintains: Outperform | $70 → $53 | $118.95 | -55.44% | 1 | Feb 24, 2023 | |
| QTRX Quanterix | Downgrades: Market Perform | $38 → $18 | $2.69 | +569.14% | 2 | Aug 9, 2022 | |
| BDSX Biodesix | Initiates: Outperform | n/a | $14.93 | - | 2 | Apr 20, 2022 | |
| EVO Evotec SE | Initiates: Outperform | n/a | $3.03 | - | 1 | Nov 29, 2021 | |
| NAUT Nautilus Biotechnology | Initiates: Outperform | n/a | $2.54 | - | 1 | Nov 2, 2021 | |
| MXCT MaxCyte | Initiates: Outperform | n/a | $1.04 | - | 1 | Aug 24, 2021 | |
| CTKB Cytek Biosciences | Initiates: Outperform | n/a | $4.01 | - | 1 | Aug 17, 2021 | |
| RPID Rapid Micro Biosystems | Initiates: Outperform | n/a | $2.06 | - | 1 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.88 | - | 1 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $460 → $470 | $144.41 | +225.46% | 4 | Apr 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.26 | +486.85% | 1 | Apr 15, 2021 |
Bruker
Aug 7, 2024
Maintains: Hold
Price Target: $74 → $72
Current: $45.69
Upside: +57.58%
BioLife Solutions
Aug 9, 2023
Maintains: Outperform
Price Target: $29 → $25
Current: $23.95
Upside: +4.38%
Guardant Health
Feb 24, 2023
Maintains: Outperform
Price Target: $70 → $53
Current: $118.95
Upside: -55.44%
Quanterix
Aug 9, 2022
Downgrades: Market Perform
Price Target: $38 → $18
Current: $2.69
Upside: +569.14%
Biodesix
Apr 20, 2022
Initiates: Outperform
Price Target: n/a
Current: $14.93
Upside: -
Evotec SE
Nov 29, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.03
Upside: -
Nautilus Biotechnology
Nov 2, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.54
Upside: -
MaxCyte
Aug 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.04
Upside: -
Cytek Biosciences
Aug 17, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Rapid Micro Biosystems
Aug 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $2.06
Upside: -
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.88
Upside: -
Apr 28, 2021
Maintains: Buy
Price Target: $460 → $470
Current: $144.41
Upside: +225.46%
Apr 15, 2021
Initiates: Buy
Price Target: $25
Current: $4.26
Upside: +486.85%